SPDR Series Trust SPDR S&P Biotech ETF (XBI)
$88.25
0.44 (0.50%)
XBI Stock Quote Delayed 30 Minutes
The 5 Biggest Stories to Watch in Q2
What catalysts and drivers will help determine this market's direction over the next few months? Here's a look at headlines to watch.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
58.09M
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
7.27M
Day's Range
$87.84 - $89.83
52-Week Range
$81.14 - $105.47
Dividend & Yield
$0.03 (0.03%)
XBI Stock Predictions, Articles, and SPDR Series Trust SPDR S&P Biotech ETF News
How to Profit From Every Biotech Buyout
Amgen's acquisition of Onyx underscores the fact that one simple biotech investment may also be the best one.
Grab These 3 Short-Term ETF Bargains While They Last
Leadership in the ETF circles has been focused on the regional and larger banks, gold miners, Internet, biotech and restaurant funds.
Changing U.S. Demographics Mean a Decades-Long Healthcare Boom
The aging of America's boomers is a compelling macro trend at work. And there's no better way to play that trend than via these ETFs.
Make a Straightforward Play in Biotech
The iShares Nasdaq Biotechology Index Fund is a great way to get into biotechs ... just not now. It's due for a buyers' exhaustion break, so wait and keep watch.
My Brilliant Biotech Move for 2012
An overly helter-skelter year in the world of biotech stocks has been a stark reminder of a basic lesson that isn't followed enough: Keep it simple.
Are You Missing the Biotech Boat?
Biotech stocks have been one of the market's best performing areas during the past year and beyond. Is it too late to catch this comet?
The Best Ways to Play Sectors Right Now
A shrinking correlation among stocks means harder decisions. Here's some sectors you should play with a fund, and others where you should go stock-picking.
